智飞生物：公司高度重视创新研发，布局了mRNA技术平台、新型佐剂技术平台等多个技术平台

Core Viewpoint - The company emphasizes its commitment to innovative research and development, focusing on multiple technology platforms including mRNA and novel adjuvants to explore various vaccine development pathways for product iteration and breakthroughs [1] Group 1 - The company has established an mRNA technology platform [1] - The company has developed a novel adjuvant technology platform [1] - The company is exploring multiple vaccine development pathways [1] Group 2 - The company aims to achieve iterative upgrades and innovative breakthroughs in its vaccine products [1] - Investors are encouraged to follow the company's information disclosures for updates on its research pipeline [1]